Two Mega-Mergers Were Just The Highlights Of A Year Of Major Deals
BMS/Celgene and AbbVie/Allergan were the biggest biopharma deals by dollar value in 2019, and the third and seventh largest ever. The year saw 23 deals valued at $1bn or more, including 20 M&A agreements.
You may also be interested in...
Seagen, With Two Big Pharma Bidders, Nearly Lost Both
Seagen was being pursued by another prospective big pharma buyer when it engaged Pfizer in merger negotiations, but both bidders walked away in late summer 2022; Pfizer returned in January.
Pfizer-gen? Pfizer Is The Latest Rumored Suitor For Seagen
Pfizer and Seagen reportedly are in merger discussions, signaling Pfizer’s willingness to invest significantly in antibody-drug conjugates (ADCs) for cancer.
The Pandemic Hurt, But EY Expects More Biopharma Deal-Making In 2021
COVID-19 drove down both deal-making and biopharma “firepower” for part of 2020, but the industry began rebounding. This year should see significant bolt-on M&A activity and technology-driven alliances, according to EY.